Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Staphylococcus aureus Leukocidins Target Endothelial DARC to Cause Lethality in Mice.

Lubkin A, Lee WL, Alonzo F 3rd, Wang C, Aligo J, Keller M, Girgis NM, Reyes-Robles T, Chan R, O'Malley A, Buckley P, Vozhilla N, Vasquez MT, Su J, Sugiyama M, Yeung ST, Coffre M, Bajwa S, Chen E, Martin P, Kim SY, Loomis C, Worthen GS, Shopsin B, Khanna KM, Weinstock D, Lynch AS, Koralov SB, Loke P, Cadwell K, Torres VJ.

Cell Host Microbe. 2019 Mar 13;25(3):463-470.e9. doi: 10.1016/j.chom.2019.01.015. Epub 2019 Feb 21.

PMID:
30799265
2.

Identification of biologic agents to neutralize the bicomponent leukocidins of Staphylococcus aureus.

Chan R, Buckley PT, O'Malley A, Sause WE, Alonzo F 3rd, Lubkin A, Boguslawski KM, Payne A, Fernandez J, Strohl WR, Whitaker B, Lynch AS, Torres VJ.

Sci Transl Med. 2019 Jan 16;11(475). pii: eaat0882. doi: 10.1126/scitranslmed.aat0882.

PMID:
30651319
3.

Staphylococcus aureus Strain Newman D2C Contains Mutations in Major Regulatory Pathways That Cripple Its Pathogenesis.

Sause WE, Copin R, O'Malley A, Chan R, Morrow BJ, Buckley PT, Fernandez J, Lynch AS, Shopsin B, Torres VJ.

J Bacteriol. 2017 Nov 14;199(24). pii: e00476-17. doi: 10.1128/JB.00476-17. Print 2017 Dec 15.

4.

Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.

Ma Z, Lynch AS.

J Med Chem. 2016 Jul 28;59(14):6645-57. doi: 10.1021/acs.jmedchem.6b00485. Epub 2016 Jul 9.

PMID:
27336583
5.

A peptide immunization approach to counteract a Staphylococcus aureus protease defense against host immunity.

Jordan RE, Fernandez J, Brezski RJ, Greenplate AR, Knight DM, Raju TS, Lynch AS.

Immunol Lett. 2016 Apr;172:29-39. doi: 10.1016/j.imlet.2016.02.009. Epub 2016 Feb 18.

PMID:
26905931
6.

Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.

Sause WE, Buckley PT, Strohl WR, Lynch AS, Torres VJ.

Trends Pharmacol Sci. 2016 Mar;37(3):231-241. doi: 10.1016/j.tips.2015.11.008. Epub 2015 Dec 22. Review.

7.

Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States.

Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison MJ, Shang W, Williams MM, Bowden KE, Burgos-Rivera B, Qin X, Messonnier N, Tondella ML.

Clin Vaccine Immunol. 2014 Feb;21(2):119-25. doi: 10.1128/CVI.00717-13. Epub 2013 Nov 20.

8.

Evaluation of the in vitro activities of ceftobiprole and comparators in staphylococcal colony or microtitre plate biofilm assays.

Abbanat D, Shang W, Amsler K, Santoro C, Baum E, Crespo-Carbone S, Lynch AS.

Int J Antimicrob Agents. 2014 Jan;43(1):32-9. doi: 10.1016/j.ijantimicag.2013.09.013. Epub 2013 Oct 24.

PMID:
24252780
9.

Assessment of the combination of doripenem plus a fluoroquinolone against non-susceptible Acinetobacter baumannii isolates from nosocomial pneumonia patients.

Queenan AM, Davies TA, He W, Lynch AS.

J Chemother. 2013 Jun;25(3):141-7. doi: 10.1179/1973947813Y.0000000074.

PMID:
23783138
10.

Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program.

Morrow BJ, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA.

Diagn Microbiol Infect Dis. 2013 Apr;75(4):412-6. doi: 10.1016/j.diagmicrobio.2012.12.012. Epub 2013 Feb 5.

PMID:
23391609
11.

In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.

He W, Kaniga K, Lynch AS, Flamm RK, Davies TA.

Diagn Microbiol Infect Dis. 2012 Dec;74(4):417-9. doi: 10.1016/j.diagmicrobio.2012.08.014. Epub 2012 Sep 17.

PMID:
22995366
12.

Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010.

Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA.

Diagn Microbiol Infect Dis. 2012 Jul;73(3):267-70. doi: 10.1016/j.diagmicrobio.2012.04.002. Epub 2012 May 12.

PMID:
22579652
13.

Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone.

Davies TA, Flamm RK, Lynch AS.

Int J Antimicrob Agents. 2012 Jun;39(6):534-8. doi: 10.1016/j.ijantimicag.2012.02.016. Epub 2012 Apr 21.

PMID:
22526015
14.

Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.

Fernandez J, Abbanat D, Shang W, He W, Amsler K, Hastings J, Queenan AM, Melton JL, Barron AM, Flamm RK, Lynch AS.

Antimicrob Agents Chemother. 2012 Mar;56(3):1476-84. doi: 10.1128/AAC.06057-11. Epub 2012 Jan 9.

15.

Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections.

Fernandez J, Hilliard JJ, Morrow BJ, Melton JL, Flamm RK, Barron AM, Lynch AS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5522-8. doi: 10.1128/AAC.00471-11. Epub 2011 Sep 12.

16.

Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.

Morrow BJ, Abbanat D, Baum EZ, Crespo-Carbone SM, Davies TA, He W, Shang W, Queenan AM, Lynch AS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21. doi: 10.1128/AAC.00470-11. Epub 2011 Sep 12.

17.

Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.

Davies TA, Marie Queenan A, Morrow BJ, Shang W, Amsler K, He W, Lynch AS, Pillar C, Flamm RK.

J Antimicrob Chemother. 2011 Oct;66(10):2298-307. doi: 10.1093/jac/dkr290. Epub 2011 Jul 20.

PMID:
21775338
18.

Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.

Hilliard JJ, Melton JL, Hall L, Abbanat D, Fernandez J, Ward CK, Bunting RA, Barron A, Lynch AS, Flamm RK.

Antimicrob Agents Chemother. 2011 Feb;55(2):836-44. doi: 10.1128/AAC.00670-10. Epub 2010 Dec 6.

19.

New antibiotic agents and approaches to treat biofilm-associated infections.

Lynch AS, Abbanat D.

Expert Opin Ther Pat. 2010 Oct;20(10):1373-87. doi: 10.1517/13543776.2010.505923. Review.

PMID:
20636186
20.

In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.

Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K.

Antimicrob Agents Chemother. 2010 May;54(5):1955-64. doi: 10.1128/AAC.01374-09. Epub 2010 Feb 22.

21.

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.

Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS.

Antimicrob Agents Chemother. 2008 Jul;52(7):2313-23. doi: 10.1128/AAC.01649-07. Epub 2008 Apr 28.

22.

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci.

Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS.

Antimicrob Agents Chemother. 2008 Jul;52(7):2324-34. doi: 10.1128/AAC.01651-07. Epub 2008 Apr 28.

23.

Methods to identify and characterize inhibitors of bacterial RNA polymerase.

Lynch AS, Du Q.

Methods Mol Med. 2008;142:37-51. doi: 10.1007/978-1-59745-246-5_4.

PMID:
18437304
24.

Bacterial and fungal biofilm infections.

Lynch AS, Robertson GT.

Annu Rev Med. 2008;59:415-28. Review.

PMID:
17937586
25.

Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins.

Li J, Ma Z, Chapo K, Yan D, Lynch AS, Ding CZ.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5510-3. Epub 2007 Aug 28.

PMID:
17826091
26.

A Novel indole compound that inhibits Pseudomonas aeruginosa growth by targeting MreB is a substrate for MexAB-OprM.

Robertson GT, Doyle TB, Du Q, Duncan L, Mdluli KE, Lynch AS.

J Bacteriol. 2007 Oct;189(19):6870-81. Epub 2007 Jul 20.

27.

New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.

Combrink KD, Denton DA, Harran S, Ma Z, Chapo K, Yan D, Bonventre E, Roche ED, Doyle TB, Robertson GT, Lynch AS.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):522-6. Epub 2006 Oct 12.

PMID:
17070048
28.

Design, synthesis, and biological evaluation of BODIPY-erythromycin probes for bacterial ribosomes.

Li J, Kim IH, Roche ED, Beeman D, Lynch AS, Ding CZ, Ma Z.

Bioorg Med Chem Lett. 2006 Feb 15;16(4):794-7. Epub 2005 Nov 23.

PMID:
16309904
29.

Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view.

Lynch AS.

Biochem Pharmacol. 2006 Mar 30;71(7):949-56. Epub 2005 Nov 14. Review.

PMID:
16290174
31.

Antimicrobial Resistance -- 2005 Annual Conference. Science -- prevention -- control.

Lynch AS.

IDrugs. 2005 Sep;8(9):697-700. No abstract available.

PMID:
16118684
32.

Antibacterial Drug Discovery and Development Summit - Tenth Annual SRI Summit.

Lynch AS.

IDrugs. 2005 May;8(5):395-8. No abstract available.

PMID:
15883920
33.

A new class of bacterial RNA polymerase inhibitor affects nucleotide addition.

Artsimovitch I, Chu C, Lynch AS, Landick R.

Science. 2003 Oct 24;302(5645):650-4.

34.

On the molecular basis of the thermal sensitivity of an Escherichia coli topA mutant.

Wang Y, Lynch AS, Chen SJ, Wang JC.

J Biol Chem. 2002 Jan 11;277(2):1203-9. Epub 2001 Nov 7.

35.

The ArcB sensor kinase of Escherichia coli: genetic exploration of the transmembrane region.

Kwon O, Georgellis D, Lynch AS, Boyd D, Lin EC.

J Bacteriol. 2000 May;182(10):2960-6.

36.

Structure of the RNA polymerase domain of E. coli primase.

Keck JL, Roche DD, Lynch AS, Berger JM.

Science. 2000 Mar 31;287(5462):2482-6.

37.

The ephrin VAB-2/EFN-1 functions in neuronal signaling to regulate epidermal morphogenesis in C. elegans.

Chin-Sang ID, George SE, Ding M, Moseley SL, Lynch AS, Chisholm AD.

Cell. 1999 Dec 23;99(7):781-90.

38.

A mutational study of the ArcA-P binding sequences in the aldA promoter of Escherichia coli.

Pellicer MT, Lynch AS, De Wulf P, Boyd D, Aguilar J, Lin EC.

Mol Gen Genet. 1999 Feb;261(1):170-6.

PMID:
10071223
39.
40.

The expression of a C. elegans neurotransmitter transporter gene (T25B6.7).

James CT, MacGregor D, Lynch AS, Coates D, Isaac RE.

Biochem Soc Trans. 1997 Aug;25(3):553S. No abstract available.

PMID:
9388767
41.

Characterisation of ZK643-3: a putative 7TM neuropeptide receptor.

Coates D, Briggs DA, MacGregor D, Lynch AS, Kolakowski LF, Hope IA, Isaac RE.

Biochem Soc Trans. 1997 Aug;25(3):440S. No abstract available.

PMID:
9388664
42.
44.

The C. elegans expression pattern database: a beginning.

Hope IA, Albertson DG, Martinelli SD, Lynch AS, Sonnhammer E, Durbin R.

Trends Genet. 1996 Sep;12(9):370-1. No abstract available.

PMID:
8855668
45.

Molecular dissection of a protein SopB essential for Escherichia coli F plasmid partition.

Hanai R, Liu R, Benedetti P, Caron PR, Lynch AS, Wang JC.

J Biol Chem. 1996 Jul 19;271(29):17469-75.

46.
47.

SopB protein-mediated silencing of genes linked to the sopC locus of Escherichia coli F plasmid.

Lynch AS, Wang JC.

Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):1896-900.

50.

Transcription and DNA supercoiling.

Wang JC, Lynch AS.

Curr Opin Genet Dev. 1993 Oct;3(5):764-8. Review.

PMID:
8274860

Supplemental Content

Loading ...
Support Center